Industry Symposium by Siemens Healthineers and Bayer

IND 10 - Meeting clinical needs in prostate cancer with MRI, next-generation imaging and theranostics

As prostate cancer cases continue to rise in Europe and worldwide, the importance of early diagnosis and better therapeutic strategies becomes increasingly crucial for personalized patient management. In this symposium, experts from different disciplines will navigate the impact of imaging at various states of the prostate cancer patient journey, offering valuable insights and clinical cases examples.


Key discussion topics will be:

- The urologist’s perspective on the MRI-pathway implementation in screening and early detection.

- Staging prostate cancer with next-generation imaging.

- Exploring clinical management opportunities offered by theragnostic.


Join this symposium featuring case-based discussions for practical takeaways, making it an opportunity to stay informed about how modern imaging affects prostate cancer management.

IND 10-1
15 min
Meeting clinical needs in prostate cancer with MRI, next-generation imaging and theranostics
Anwar R. Padhani, Northwood / United Kingdom
Understanding the Development of New Therapy Paradigms: 

Recognize that new therapy paradigms in prostate cancer care are rooted in a deep understanding of clinical needs and priorities at various stages of the prostate cancer patient journey. 

Explore the transformative potential of integrating various digital technologies, such as next-generation imaging, objective analyses, visualization, and artificial intelligence, within the innovation cycle. 

Addressing Clinical Needs in Early Disease Detection and Therapy: 

Understand the pivotal role of artificial intelligence in addressing clinical needs for cancer detection. 

Familiarize with the potential benefits of theragnostic strategies in managing metastatic castration-resistant disease. 

Enhanced Learning through Case-Based Illustrations: 

Enhance participants' understanding of clinical needs and digital technologies through case-based illustrations. 

Emphasize the significance of clinical trials focused on validating imaging biomarkers and addressing bias mitigations, particularly within the context of emerging therapy paradigms. 
IND 10-2
15 min
The MRI-pathway implementation in prostate cancer screening and early detection
Francesco Sanguedolce, Barcelona / Spain
IND 10-3
15 min
Staging prostate cancer with next-generation imaging
Giuseppe Petralia, Milano / Italy
IND 10-4
15 min
Theranostics of prostate cancer
Wolfgang Weber, München / Germany

Lectures

1
Meeting clinical needs in prostate cancer with MRI, next-generation imaging and theranostics

Meeting clinical needs in prostate cancer with MRI, next-generation imaging and theranostics

15:00Anwar R. Padhani, Northwood / UK

2
The MRI-pathway implementation in prostate cancer screening and early detection

The MRI-pathway implementation in prostate cancer screening and early detection

15:00Francesco Sanguedolce, Barcelona / ES

3
Staging prostate cancer with next-generation imaging

Staging prostate cancer with next-generation imaging

15:00Giuseppe Petralia, Milano / IT

4
Theranostics of prostate cancer

Theranostics of prostate cancer

--:--Wolfgang Weber, München / DE